SPVN 06
Alternative Names: SPVN-06Latest Information Update: 28 Sep 2024
At a glance
- Originator Institut de la Vision
- Developer SparingVision
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Retinitis pigmentosa
- No development reported Retinal dystrophies
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Retinal dystrophies in France (Subretinal, Injection)
- 24 Jan 2024 SparingVision plans an IND-enabling study for Dry macular degeneration (Subretinal, injection) in 2024
- 30 Aug 2023 Adverse events data from a phase I/II PRODYGY trial in Retinitis pigmentosa released by SparingVision